Petro Terblanche, Afrigen Biologics managing director (Kristin Palitza/picture-alliance/dpa/AP Images)

September 23, 2022 11:22 AM EDTUpdated 04:36 PM

WHO-backed Afrigen plans a charge toward the clinic with Africa's first Covid-19 vaccine

Aayushi Pratap

News Reporter

NEW YORK — When vaccines from high-income countries did not arrive in Africa, a local WHO-backed company decided to take the matter into its own …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

WHO-backed Afrigen plans a charge toward the clinic with Africa's first Covid-19 vaccine

Aayushi Pratap

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

WHO-backed Afrigen plans a charge to­ward the clin­ic with Africa's first Covid-19 vac­cine

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

WHO-backed Afrigen plans a charge toward the clinic with Africa's first Covid-19 vaccine